Continuing his discussion at the AUA 2024 Annual Meeting, Vikram M. Narayan, MD, of Emory University School of Medicine, highlights the latest study on nadofaragene firadenovec. This investigation looked at urinary minimal residual disease detection for predicting recurrence in BCG-unresponsive non-muscle invasive bladder cancer and for quantifying molecular response to the therapy. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Intravesical EMDA/MMC can serve as a safe and effective option for patients with high-risk NMIBC who fail BCG therapy.
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
uMRD profiling determines mutations connected with urothelial carcinoma through next-generation sequencing.
Patients received weekly doses of docetaxel 80 mg, gemcitabine 1000 mg or 2000 mg, and biweekly cisplatin 100 mg.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Advertisement
Advertisement
Latest News
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
